Pyxis Oncology, an immuno-oncology company developing antibody drugs to restore activity to dysfunctional T cells, has appointed Ronald Herbst as its chief scientific officer. Herbst joins the Boston-based company from the AstraZeneca (NYSE: AZN) global biologics R&D arm, MedImmune, where he was vice president of research and development and head of oncology research.
From Our Partners · Special Report
Advice for funding and future transformational opportunities
Sponsored · Whitepaper
Explore the different sources of funding, their relative merits, and how you should best utilize that funding at each stage of your research
Brex
Sponsored · Special Report
Hyperinflation in rents is over
Hughes Marino
